In preclinical studies, brivanib administration demonstrated encouraging results in different cancer models, but it mostly led to tumor inhibition rather than tumor regression and its efficacy depended on endogenous bFGF expression [117,118]. This evidence concerns the gene FGF2 and neoplasm.